Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 627126, 6 pages
http://dx.doi.org/10.1155/2014/627126
Research Article

Serum Levels of Three Angiogenic Factors in Systemic Lupus Erythematosus and Their Clinical Significance

1Department of Nephrology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu 215006, China
2Department of Rheumatology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu 215006, China

Received 27 October 2013; Accepted 4 December 2013; Published 6 January 2014

Academic Editor: Miguel A. Gonzalez-Gay

Copyright © 2014 Ling Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Cieślik, A. Hrycek, and P. Kłuciński, “Vasculopathy and vasculitis in systemic lupus erythematosus,” Polskie Archiwum Medycyny Wewne, vol. 118, no. 1-2, pp. 57–63, 2008. View at Google Scholar
  2. R. López-Mejías, A. Corrales, F. Genre et al., “Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 31, no. 5, pp. 761–766, 2013. View at Google Scholar
  3. F. Genre, J. A. Miranda-Filloy, R. López-Mejias et al., “Antitumour necrosis factor-a therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients,” Annals of the Rheumatic Diseases, vol. 72, no. 7, pp. 1265–1267, 2013. View at Google Scholar
  4. N. Maruotti, F. P. Cantatore, B. Nico, A. Vacca, and D. Ribatti, “Angiogenesis in vasculitides,” Clinical and Experimental Rheumatology, vol. 26, no. 3, pp. 476–483, 2008. View at Google Scholar · View at Scopus
  5. B. Rueda, M. A. Lopez-Nevot, M. J. Lopez-Diaz, C. Garcia-Porrua, J. Martín, and M. A. Gonzalez-Gay, “A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis,” Journal of Rheumatology, vol. 32, no. 9, pp. 1737–1741, 2005. View at Google Scholar · View at Scopus
  6. L. Rodríguez-Rodríguez, M. García-Bermúdez, C. González-Juanatey et al., “Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients,” Tissue Antigens, vol. 77, no. 4, pp. 291–297, 2011. View at Google Scholar
  7. C. Navarro, L. Candia-Zúñiga, L. H. Silveira et al., “Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome,” Lupus, vol. 11, no. 1, pp. 21–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Szekanecz and A. E. Koch, “Vascular involvement in rheumatic diseases: ‘Vascular rheumatology’,” Arthritis Research and Therapy, vol. 10, no. 5, article 224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. D'Cruz, “Vasculitis in systemic lupus erythematosus,” Lupus, vol. 7, no. 4, pp. 270–274, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. N. M. Heshmat and T. H. El-Kerdany, “Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus,” Pediatric Allergy and Immunology, vol. 18, no. 4, pp. 346–353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Robak, A. Wóniacka, A. Sysa-Jȩdrzejowska, H. Stȩpień, and T. Robak, “Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity,” European Cytokine Network, vol. 12, no. 3, pp. 445–452, 2001. View at Google Scholar · View at Scopus
  12. N. Maruotti, T. Annese, F. P. Cantatore, and D. Ribatti, “Macrophages and angiogenesis in rheumatic diseases,” Vascular Cell, vol. 5, no. 1, p. 11, 2013. View at Google Scholar
  13. E. Robak, A. Sysa-Jȩdrzejewska, and T. Robak, “Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus,” Mediators of Inflammation, vol. 12, no. 5, pp. 293–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Carmeliet, L. Moons, A. Luttun et al., “Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions,” Nature Medicine, vol. 7, no. 5, pp. 575–583, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Bottomley, N. J. A. Webb, C. J. Watson et al., “Placenta growth factor (PIGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid,” Clinical and Experimental Immunology, vol. 119, no. 1, pp. 182–188, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Sbaa, J. DeWever, P. Martinive et al., “Caveolin plays a central role in endothelial progenitor cell mobilization and homing in SDF-1-driven postischemic vasculogenesis,” Circulation Research, vol. 98, no. 9, pp. 1219–1227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Oura, J. Bertoncini, P. Velasco, L. F. Brown, P. Carmeliet, and M. Detmar, “A critical role of placental growth factor in the induction of inflammation and edema formation,” Blood, vol. 101, no. 2, pp. 560–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Robak, L. Kulczycka, A. Sysa-Jȩdrzejowska, A. Wierzbowska, and T. Robak, “Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus,” European Cytokine Network, vol. 18, no. 4, pp. 181–187, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Seghezzi, S. Patel, C. J. Ren et al., “Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis,” Journal of Cell Biology, vol. 141, no. 7, pp. 1659–1673, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Hrycek, J. Janowska, and P. Cieślik, “Selected angiogenic cytokines in systemic lupus erythematosus patients,” Autoimmunity, vol. 42, no. 5, pp. 459–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Frieri, “Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches,” Current Allergy and Asthma Reports, vol. 12, no. 1, pp. 25–32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Maruotti, F. P. Cantatore, and D. Ribatti, “Thalidomide in treatment of connective diseases and vasculities,” Reumatismo, vol. 58, no. 3, pp. 187–190, 2006. View at Google Scholar
  23. M. Walchner, M. Meurer, G. Plewig, and G. Messer, “Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus,” International Journal of Dermatology, vol. 39, no. 5, pp. 383–388, 2000. View at Google Scholar